Please login to the form below

Not currently logged in

Novartis eyes potential new indication for Cosentyx

Novartis HQ

Unveils positive late-stage results in axial spondyloarthritis

Acceleron scraps rare muscular dystrophy drug

AcceleronClinical profile not strong enough to push into late-stage testing

J&J's Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

New data backs GeNeuro’s MS drug after Servier exit

Brain scanSearch continues for new development partner

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

Aimmune gets FDA panel backing for peanut allergy therapy

AimmuneStep closer to becoming first approved treatment

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

AstraZeneca AZRaces to become first-in-class

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Lundbeck HQContinues to bulk up its pipeline

AbbVie/Allergan's merger faces public opposition

AbbVie RedwoodAdvocacy groups and unions in the US express concerns

Jessica Pacey 2Q&A: Jessica Pacey

PME interviews the founder and chief executive of newly launched health comms agency, 67health

Featured jobs

Subscribe to our email news alerts


Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
Its Know Your Numbers week
Do you know yours?...